Subscribe
shutterstock_1397823521_pavel_kapysh
Pavel Kapysh / Shutterstock.com
27 September 2022BiotechnologyStaff Writer

Bio-Techne takes patent dispute to UK

The lawsuit centres on patented molecular instruments | The patents-in-suit cover cover features of RNAscope tech.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pfizer acquires AstraZeneca’s small molecule anti-infective business
25 August 2016   Pharmaceutical company Pfizer has acquired AstraZeneca’s small molecule anti-infective business.
Biotechnology
LES 2015: ‘Much unrest’ in molecular diagnostics area, argues Roche
28 October 2015   There is “clearly a lot of unrest” in the patent law on molecular diagnostics, according to the head of licensing at Roche Diagnostics.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle